Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 65

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 4
Chunk 65
---
 promote our strong primary care portfolio, with the Japanese government driving stricter control of drug prices and promoting the penetration of generics, our strategy is to shift focus more towards the uptake of our highly innovative and differentiated specialty medicines such asENTYVIO, GATTEX/REVESTIVE, TAKECAB, TRINTELLIX and TAKHZYRO. Furthermore, four new products - ADZYNMA, OBIZUR, LIVTENCITY and CEPROTIN - were launched in FY2024, along with the introduction of a new2-dose vial of NUVAXOVID for Omicron JN.1, to further drive revenue growth.

The Global Portfolio Division (“ GPD”) is focused on accelerating our growth throug h a global footprint, as well as a diverse portfolio and pipeline of transformational medicines and vaccines. The GPD comprises the China, EUCAN (defined below), GEM (defined below) and Global Vaccine Business Units, and the Global Medical and Global Product & Launch Strategy (“ GPLS”) functions.

The Europe and Canada (“ EUCAN”) business unit focuses on a specialized approach in the European and Canadian markets, where public insurance has set a high bar for the reimbursement of medicines, requiring innovation and clear differentiation in order for products to be reimbursed. The EUCAN business unit is focused on continuing to grow core products such as ENTYVIO, TAKHZYRO, ELVANSE/VYVANSE, and our immunoglobulin products and recently approved products such as LIVTENCITY.

The China Business Unit (“ China BU”) focuses on unleashing the growth potential in the world’s second largest pharmaceutical market. The China BU continues to maximize the value of brands such as ENTYVIO, ADCETRIS, TAKHZYRO, REPLAGAL, ALUNBRIG, LIVTENCITY andHUMAN ALBUMIN/FLEXBUMIN while also aiming to bring more new medicines and treatment options to China in the future from the therapeutic areas of Gastrointestinal and Inflammation, Neuroscience, Oncology, and Rare Genetics and Hematology.

Table of Contents

The Growth and Emerging Markets (“ GEM”) Business Unit is focused on delivering highly innovative medicines to patients in GEM countries living with complex and rare diseases i n our six key business areas of GI, Rare Diseases, PDT, Oncology, Vaccines and Neuroscience.

The Oncology Business Unit (“ OB U”) is focused on the development and marketing of